Skip to main content
menu

CiTI: a Centre for Inflammation and Therapeutic Innovation

Doctoral Training Programmes

UCB Pharma – UCLPartners PhD student programme

CiTI, in collaboration with UCB Pharma and UCLPartners are pleased to announce the formation of a new PhD student programme commencing in October 2017. The ambition of this programme is to combine the scientific excellence available at UCL, QMUL and UCB within inflammation sciences and affiliated disciplines. Moreover, this scheme will provide a coordinated and innovative approach to basic and translational science, drug discovery and therapeutic strategies.

Two to four studentships will be available over the next 4 years and will focus on one of the following 6 key areas of research.

  • Vascular Inflammation and Cell Trafficking
  • Fibrotic Inflammation
  • Reparative and Regenerative Therapeutics  
  • Stromal cell biology (Tissue around Inflammation and/or Tumour)
  • Bone Inflammation

 A workshop at UCB in Slough will take place in November 2017 to discuss the individual PhD project proposals for 2018 and to highlight the expertise and technologies available at UCB.  To find out more about the first workshop held in March 2017 please read the article:  UCLPartners UCB workshop [PDF 1,148KB].

One PhD studentship in Prof Dell'Accio's lab at QMUL is now available to apply for. The deadline for applications is the 30th of June 2018. For further information and details of how to apply please go to the FindaPhD website

EVOluTION

EVOluTION (European Vascular Intervention and Therapeutic Innovation)is a Marie Sklodowska-Curie Actions Innovative Training Network (ITN) doctoral programme that commenced in April 2016. Eleven PhD students are part of this network and are currently being trained on various aspects of drug discovery and development including: preclinical and clinical research, commercial and business opportunities and intellectual property. The research themes of EVOluTION are focused on boosting the natural protective mechanisms operating in our body, to generate innovative therapeutic strategies in the management of chronic vascular and metabolic diseases. To find out more please visit the EVOluTION website.

 

Return to top